Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial

SMD Mees, A Algra, WP Vandertop, Fop Kooten, HAJM Kuijsten, J Boiten, RJ van Oostenbrugge, RA Salman, PM Lavados, GJE Rinkel, WM Bergh

Research output: Contribution to journalArticleAcademicpeer-review

196 Citations (Scopus)

Abstract

Background Magnesium sulphate is a neuroprotective agent that might improve outcome after aneurysmal subarachnoid haemorrhage by reducing the occurrence or improving the outcome of delayed cerebral ischaemia. We did a trial to test whether magnesium therapy improves outcome after aneurysmal subarachnoid haemorrhage. Methods We did this phase 3 randomised, placebo-controlled trial in eight centres in Europe and South America. We randomly assigned (with computer-generated random numbers, with permuted blocks of four, stratified by centre) patients aged 18 years or older with an aneurysmal pattern of subarachnoid haemorrhage on brain imaging who were admitted to hospital within 4 days of haemorrhage, to receive intravenous magnesium sulphate, 64 mmol/day, or placebo. We excluded patients with renal failure or Findings 1204 patients were enrolled, one of whom had his treatment allocation lost. 606 patients were assigned to the magnesium group (two lost to follow-up), 597 to the placebo (one lost to follow-up). 158 patients (26.2%) had poor outcome in the magnesium group compared with 151 (25.3%) in the placebo group (risk ratio [RR] 1.03, 95% CI 0.85-1.25). Our updated meta-analysis of seven randomised trials involving 2047 patients shows that magnesium is not superior to placebo for reduction of poor Interpretation Intravenous magnesium sulphate does not improve clinical outcome after aneurysmal subarachnoid haemorrhage, therefore routine administration of magnesium cannot be recommended.
Original languageUndefined/Unknown
Pages (from-to)44-49
Number of pages6
JournalLancet (UK)
Volume380
Issue number9836
DOIs
Publication statusPublished - 2012

Cite this